EP4090686A4 - Pro-antibody that reduces off-target toxicity - Google Patents
Pro-antibody that reduces off-target toxicity Download PDFInfo
- Publication number
- EP4090686A4 EP4090686A4 EP21741991.0A EP21741991A EP4090686A4 EP 4090686 A4 EP4090686 A4 EP 4090686A4 EP 21741991 A EP21741991 A EP 21741991A EP 4090686 A4 EP4090686 A4 EP 4090686A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pro
- antibody
- reduces
- target toxicity
- toxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062962555P | 2020-01-17 | 2020-01-17 | |
PCT/US2021/013688 WO2021146590A2 (en) | 2020-01-17 | 2021-01-15 | Pro-antibody that reduces off-target toxicity |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4090686A2 EP4090686A2 (en) | 2022-11-23 |
EP4090686A4 true EP4090686A4 (en) | 2024-03-27 |
Family
ID=82906067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21741991.0A Pending EP4090686A4 (en) | 2020-01-17 | 2021-01-15 | Pro-antibody that reduces off-target toxicity |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4090686A4 (en) |
CN (1) | CN114945597A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017156178A1 (en) * | 2016-03-08 | 2017-09-14 | Maverick Therapeutics, Inc. | Inducible binding proteins and methods of use |
WO2019051102A2 (en) * | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY33492A (en) * | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
UA117901C2 (en) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
JP2015502397A (en) * | 2011-12-23 | 2015-01-22 | ファイザー・インク | Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor |
GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
JP2015516813A (en) * | 2012-04-27 | 2015-06-18 | シトムクス セラピューティクス,インコーポレイティド | Activable antibody binding epidermal growth factor receptor and method of use thereof |
NZ718283A (en) * | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
AU2015292406B2 (en) * | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
JP2018520642A (en) * | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Mask anti-CD3 antibody and method of use thereof |
US10822419B2 (en) * | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
EP3328427B1 (en) * | 2015-07-27 | 2024-05-29 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
JP7022080B2 (en) * | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates |
BR112019018541A2 (en) * | 2017-03-09 | 2020-04-14 | Cytomx Therapeutics Inc | cd147 antibodies, activable cd147 antibodies and methods of producing and using them |
US11364303B2 (en) * | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
EP4023230A4 (en) * | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | Antibody cleavage site-binding molecule |
WO2021195472A1 (en) * | 2020-03-26 | 2021-09-30 | Aetio Biotherapy, Inc. | Bi-specific fusion proteins for depletion of regulatory t cells |
-
2021
- 2021-01-15 CN CN202180009547.6A patent/CN114945597A/en active Pending
- 2021-01-15 EP EP21741991.0A patent/EP4090686A4/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017156178A1 (en) * | 2016-03-08 | 2017-09-14 | Maverick Therapeutics, Inc. | Inducible binding proteins and methods of use |
WO2019051102A2 (en) * | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
Non-Patent Citations (1)
Title |
---|
LANG SHANSHAN ET AL: "LegoBody: facile generation of bispecific and multi-specific antibodies", BIORXIV, 27 December 2019 (2019-12-27), XP093129094, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2019.12.25.888586v1.full.pdf> [retrieved on 20240208], DOI: 10.1101/2019.12.25.888586 * |
Also Published As
Publication number | Publication date |
---|---|
CN114945597A (en) | 2022-08-26 |
EP4090686A2 (en) | 2022-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4090686A4 (en) | Pro-antibody that reduces off-target toxicity | |
AU2021901309A0 (en) | Tr3k board | |
AU2021901191A0 (en) | Tre3k board | |
AU2021904098A0 (en) | Dabrick-a2 | |
AU2021904022A0 (en) | ColourMakesItClear | |
AU2021903826A0 (en) | Iceglass | |
AU2021903650A0 (en) | agtech | |
AU2021903423A0 (en) | Easy-Grab | |
AU2021903322A0 (en) | Eycsar | |
AU2021902982A0 (en) | P1565au03 | |
AU2021902800A0 (en) | Enviro-lid-catch | |
AU2021902772A0 (en) | MyHerculead | |
AU2021902428A0 (en) | Antenna2 | |
AU2021902077A0 (en) | Si-211 | |
AU2021901795A0 (en) | Build-A-bouquet | |
AU2021901682A0 (en) | PoPLeveLPoP | |
AU2021900733A0 (en) | Mudgutz | |
AU2021900525A0 (en) | BubbleSplint | |
AU2021900524A0 (en) | Gyroball | |
AU2021900362A0 (en) | Tab-Sleeve | |
AU2021900327A0 (en) | Ridball | |
AU2021900191A0 (en) | Omni-wheel | |
AU2021900190A0 (en) | Stumpmate | |
AU2021900077A0 (en) | CareSide | |
AU2020904618A0 (en) | SafeForce |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220712 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: IMMUNE TARGETING INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240227 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/58 20060101ALI20240221BHEP Ipc: A61P 37/02 20060101ALI20240221BHEP Ipc: A61P 17/06 20060101ALI20240221BHEP Ipc: A61P 35/00 20060101ALI20240221BHEP Ipc: C07K 16/30 20060101AFI20240221BHEP |